Analyst Price Targets — CVRX
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| February 13, 2026 11:53 am | William Plovanic | Canaccord Genuity | $10.00 | $5.69 | TheFly | CVRx price target lowered to $10 from $11 at Canaccord |
| November 6, 2025 1:45 pm | Ross Osborn | Cantor Fitzgerald | $13.00 | $9.98 | TheFly | CVRx price target raised to $13 from $11 at Cantor Fitzgerald |
| October 30, 2024 7:55 am | Matt O'Brien | Piper Sandler | $16.00 | $12.90 | StreetInsider | CVRx Inc (CVRX) PT Raised to $16 at Piper Sandler |
| September 10, 2024 7:48 am | Ross Osborn | Cantor Fitzgerald | $14.00 | $7.96 | TheFly | Cantor starts CVRx with Overweight on heart failure potential |
| July 30, 2024 6:51 am | Matt O'Brien | Piper Sandler | $13.00 | $9.27 | TheFly | CVRx price target lowered to $13 from $15 at Piper Sandler |
| July 30, 2024 6:27 am | William Plovanic | Canaccord Genuity | $15.00 | $9.27 | StreetInsider | CVRx Inc (CVRX) PT Raised to $15 at Canaccord Genuity |
| July 11, 2024 8:41 am | Frank Takkinen | Lake Street | $12.00 | $7.59 | TheFly | CVRx price target lowered to $12 from $18 at Lake Street |
| June 5, 2024 9:07 am | Frank Takkinen | Loop Capital Markets | $18.00 | $8.00 | StreetInsider | CVRx Inc (CVRX) PT Lowered to $18 at Lake Street Capital Markets |
| May 1, 2024 6:57 am | Chase Knickerbocker | Craig-Hallum | $23.00 | $9.27 | StreetInsider | Craig-Hallum Assumes CVRx Inc (CVRX) at Buy |
Latest News for CVRX
NEW YORK, March 03, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of CVRx, Inc. (“CVRx” or the “Company”) (NASDAQ: CVRX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
MINNEAPOLIS, March 02, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX), a medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, announced today the schedule of scientific presentations reviewing the science and outcomes of Barostim therapy at the Technology and Heart Failure Therapeutics 2026 (THT) meeting.…
NEW YORK, Feb. 26, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of CVRx, Inc. ("CVRx" or the "Company") (NASDAQ: CVRX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
NEW YORK, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of CVRx, Inc. (“CVRx” or the “Company”) (NASDAQ: CVRX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
NEW YORK, Feb. 19, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of CVRx, Inc. ("CVRx" or the "Company") (NASDAQ: CVRX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for CVRX.
U.S. House Trading
No House trades found for CVRX.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.